Transvaginal botulinum toxin A (BTA) injection for Bladder Pain Syndrome
Phase-Based Progress Estimates
Effectiveness
Safety
Urology Clinic (Stanford University), 1000 Welch Road, Suite 100, Palo Alto, CA
Bladder Pain Syndrome+5 More
Transvaginal botulinum toxin A (BTA) injection - DrugEligibility
18+
Female
What conditions do you have?
Select
Eligibility
18+
Female
What conditions do you have?
Select
Study Summary
Interstitial cystitis / bladder pain syndrome (IC/BPS) is a debilitating condition that affects millions of women in the United States. Women suffer from recurring pelvic pain, bladder pressure, painful bladder, urinary frequency (needing to go often) and urgency (feeling a strong need to go). Women are five times more likely to suffer from IC/BPS than men. IC/BPS is a common cause of painful bladder after excluding urinary tract infection. About one-third of women resort to opioids, thus contributing to the current opioid crisis. Sadly, there are no durable treatments and the majority of therapies are not FDA-approved for IC/BPS.
Eligible Conditions
- Bladder Pain Syndrome
- Interstitial Cystitis
Treatment Effectiveness
Effectiveness Progress
Other trials for Bladder Pain Syndrome
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Baseline through week 12
Baseline through week 12
Change from baseline in American Urological Association Symptom Score (AUASS)
Change from baseline in International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ FLUTS)
Change from baseline in O'Leary Sant (OLS) Symptom Score [Interstitial Cystitis Symptom Index (ICSI) / Interstitial Cystitis Problem Index (ICPI)]
Change from baseline in Patient Global Impression of Change (PGIC) scale
Change from baseline in Short Form 12-item Survey (SF12)
Trial Safety
Safety Progress
Other trials for Bladder Pain Syndrome
Trial Design
1 Treatment Group
Transvaginal Botulinum Toxin A (BTA) injection
1 of 1
Experimental Treatment
12 Total Participants · 1 Treatment Group
Primary Treatment: Transvaginal botulinum toxin A (BTA) injection · No Placebo Group · Phase < 1
Transvaginal Botulinum Toxin A (BTA) injection
Drug
Experimental Group · 1 Intervention: Transvaginal botulinum toxin A (BTA) injection · Intervention Types: DrugTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transvaginal botulinum toxin A (BTA) injection
2019
Completed Early Phase 1
~20
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline through week 12
Closest Location: Urology Clinic (Stanford University), 1000 Welch Road, Suite 100 · Palo Alto, CA
2021First Recorded Clinical Trial
1 TrialsResearching Bladder Pain Syndrome
1 CompletedClinical Trials
Who is running the clinical trial?
McCormick and Gabilan Faculty Fellowship AwardUNKNOWN
Stanford UniversityLead Sponsor
2,130 Previous Clinical Trials
35,668,898 Total Patients Enrolled
1 Trials studying Bladder Pain Syndrome
40 Patients Enrolled for Bladder Pain Syndrome
Amy D. Dobberfuhl, M.D.Principal InvestigatorStanford University
1 Previous Clinical Trials
15 Total Patients Enrolled
Eligibility Criteria
Age 18+ · Female Participants · 2 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:The patient is female and is considering BTA chemodenervation for the treatment of refractory IC/BPS.
You are female and have IC/BPS.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
References
- Syan, Raveen, Mason A. Briggs, John C. Olivas, Sakti Srivastava, Craig V. Comiter, and Amy D. Dobberfuhl. 2019. “Transvaginal Ultrasound Guided Trigone and Bladder Injection: A Cadaveric Feasibility Study for a Novel Route of Intradetrusor Chemodenervation”. Investigative and Clinical Urology. The Korean Urological Association. doi:10.4111/icu.2019.60.1.40.
- Dobberfuhl, Amy D., Stefanie van Uem, and Eboo Versi. 2021. “Trigone as a Diagnostic and Therapeutic Target for Bladder-centric Interstitial Cystitis/bladder Pain Syndrome”. International Urogynecology Journal. Springer Science and Business Media LLC. doi:10.1007/s00192-021-04878-9.
- Dobberfuhl, Amy D.. 2022. “Pathophysiology, Assessment, and Treatment of Overactive Bladder Symptoms in Patients with Interstitial Cystitis/bladder Pain Syndrome”. Neurourology and Urodynamics. Wiley. doi:10.1002/nau.24958.
- Amy Diane Dobberfuhl 2022. "Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05485207.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments